IMMUNOLOGICAL AND BIOCHEMICAL PARAMETERS OF CHRONIC HEPATITIS B INFECTION AMONG PATIENTS IN DUHOK CITY – KURDISTAN REGION / IRAQ
Background: Hepatitis B virus infection (HBV) is regarded as serious public health problem and approximately two billion people are infected with the virus. The presence of HBsAg with the clinical and biochemical features of hepatitis B infection reflects onset of the infection. It is sometimes very difficult to distinguish between inactive HBV carrier and patients with active HBeAg negative chronic hepatitis B. The current study aimed to measure the immunological and biochemical markers other than HBsAg in patients with chronic hepatitis B virus (HBV) attended the infectious diseases unit at Azadi Teaching Hospital in Duhok.
Subjects and Methods: Eighty nine chronic hepatitis B patients were included in this study from June 2015 through December 2015. Serum samples were collected from each patient and measured for HBsAg, anti HBs Ab, HBeAg, anti HBe Ab, and total Anti HB core Ab by using a rapid test (PLASMATEC One Step Multi –HBV Test Device). The HBsAg level was further tested by ELISA (HBsAg ELISA Test Kit, PLASMATEC Laboratory Products). The HBeAg & HBeAb were confirmed by immune-chemilumencense assay. Levels of Alanine Aminotransferase (ALT), Aspartate Transaminase (AST), and Alkaline Phosphatase (ALP) in each serum sample were also measured.
Results: Out of the 89 HBs Ag positive patients 51(57.3%) were males and 38 (42.7%) were females by using ELISA test, 21(23.6%) were positive for HBeAg, and 76 (85.4%) were positive for anti-HBe antibodies by using Chemiluminescent Immunoassay (CLIA) techniques. There were 68 cases of HBe Ag negative and anti HBe Ab positive, 13 patients were HBe Ag positive and anti HBeAb negative and only 8 cases were both HBe Ag and anti HBeAb positive. Among the male patients, 10(47.61%) and 44(57.9%) were positive for HBeAg and anti-HBe antibodies respectively, whereas for the females, 11(52.40%) and 32(42.10%) patients were positive for HBeAg and anti-HBeAb respectively. Regarding the ALT, 11(12.35%) were upper than normal range in which 7 (7.9%) were elevated (40-80 IU/mL) and 4 (4.5%) were twice upper than normal limit (>80). For AST, 12 (13.48%) patients were upper than normal range in which 11(12.35%) were elevated and only 1 (1.12%) was twice upper than normal range. In ALP, only 7(7.9%) of the patients were upper than reference range.
Conclusion: From the current study, it has been concluded that HBeAg and anti Hbe Ab are dependable indicators for the active stage of HBV replication in carrier patients when both of these variables are linked with elevated levels of serum ALT. Furthermore, most increased levels of HBsAg quantitatively were found among the early and young adults who were in the age range of (24- 44) years.
2. Musa BM, Bussell S, Borodo MM, Samaila AA, Femi.OL. Prevalence of B virus infection in Nigeria, 20002013 A systemic review of Metaanalysis. Niger J. (Clin pract.2015; (2): 163-72).
3. Tarky AM, Akram W, Al-Naaimi AS, Omer AR. Epidemiology of viral hepatitis B and C in Iraq:a national survey 2005-2006. Zanco J. Med. Sci. 2013; 17:370-80.
4. Aspinall EJ, Hawkins GA, FraserA, Hutchinson S J, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: A review. Occupational Medicine. 2011; 61 (53):531-540.
5. Bowden S. Laboratory diagnosis of hepatitis B infection. In: Hepatitis B Virus. (Ed. Lai, C. L. and S. Locarnini). International Medical Press, London, UK. pp. 2002. 145159.
6. Matthews G, Robotin M. B Positive - all you wanted to know about hepatitis B: A guide for primary care providers. Australasian Society for HIV Medicine (ASHM). 2008; pp: 31-39.
7. Islam MDU, Ahmed RU, Kibria SG, Hossain MT, Biswas, et al. Clinical Significance Of Serum HbeAg Among HbsAg Positive Patients, Faridpur Med. Coll. J. 2010; 5(2):50-52.
8. HanY, Tang Q, Zhu W, Zhang X, You L. Clinical, biochemical, immunological and virological profiles of and differential diagnosis between, patients with acute hepatitis B and chronic hepatitis B with acute
flare. J. Gastroenterol. Hepatol. . 2008; (23): 1728-1733.
9. Krajden M, McNabb G, Patrick M. The laboratory diagnosis of hepatitis B virus. Can J Infect Dis Med Microbiol..2005; 16(2):65.
10. Sablon E. Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int. J. Med. Sci. 2005 (2): 8-16.
11. Milich D, Liang T. J. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection.; Hepatology. 2003 (38): 1075-86.
12. Hadziyannis S J, Papatheodoridis G V. Hepatitis B e antigen negative chronic hepatitis B natural history and treatment. Semin line Dis. 2006, (26):150-141.
13. Brunetto M R, Oliveri F, Coco B, Leonardo G, Colombatto P Gorin J M, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients. J Hepatol; 2002. (36):263-270.
14. Asadur R, Fhamid JA, Farjana R, Rashid N, Department of Immunology, Popular Diagnostic Centre Ltd., Dhaka-1205, Bangladesh. Journal of Bangladesh Academy of Sciences. 2013; (37), No. 1, 51-56.
15. Jake L, Hepatitis B: The Virus and Disease and Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, MD. Hepatology. 2009 May; 49(5 Suppl): S13–S21. doi:10.1002/hep.22881.
16. Hussain AB, Karamar KA, Anwar M, Kazmi SY, Tariq WU. Correlation of HBV DNA PCR and HBeAg in
hepatitis carriers. J Coll Physicians Surg Pak. 2004; 14:18-20.
17. Stroffoliniand and et al. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. Journal of Hepatology. 2000; 33: 116-120.
18. Saikia et al. 2007. World Health Organization. Geographic patterns of hepatitis B prevalence. . 2010. The World Health Organizations pages on vaccines and immunizations. (http://www.who.int/vaccinessurveilan ce/graphics/htmls/hepbprev.html, accessed 20 January.
19. Croagh CM, Desmond PV, Bell SJ. Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance.
World J Hepatol .2015; 7: 289-303 [PMID: 25848459 DOI: 10.4254/wjh.v7.i3.289].
20. McMahon BJ. Chronic Hepatitis B: Update HEPATOLOGY, AASLD PRACTICE GUIDELINE UPDATE. 2009.
21. Patrizia C, Rita C, Giancarlo I, Bianca B. HBV mutations and infection management WJG|www.wjgnet.com 151 January 7, 2016;Volume 22|Issue 1| World J Gastroenterol. 2016 January 7; 22(1): 145-154 ISSN 10079327 (print) ISSN 2219-2840